Onconetix Past Earnings Performance
Past criteria checks 0/6
Onconetix's earnings have been declining at an average annual rate of -73.1%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 169.5% per year.
Key information
-73.1%
Earnings growth rate
-30.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 169.5% |
| Return on equity | n/a |
| Net Margin | -6,019.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation
Jan 24
Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia
Oct 11Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot
Aug 17Blue Water Vaccines in pact to study Alzheimer’s vaccine
Jul 20Blue Water Vaccines: Estimates And Expectations
May 17Revenue & Expenses Breakdown
How Onconetix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -46 | 15 | 1 |
| 31 Dec 23 | 0 | -37 | 13 | 2 |
| 30 Sep 23 | 0 | -18 | 10 | 3 |
| 30 Jun 23 | 0 | -17 | 9 | 4 |
| 31 Mar 23 | 0 | -14 | 10 | 5 |
| 31 Dec 22 | 0 | -14 | 9 | 4 |
| 30 Sep 22 | 0 | -12 | 8 | 3 |
| 30 Jun 22 | 0 | -9 | 6 | 2 |
| 31 Mar 22 | 0 | -6 | 3 | 2 |
| 31 Dec 21 | 0 | -4 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
Quality Earnings: ONCO is currently unprofitable.
Growing Profit Margin: ONCO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONCO is unprofitable, and losses have increased over the past 5 years at a rate of 73.1% per year.
Accelerating Growth: Unable to compare ONCO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ONCO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.